Optimization of whole-body positron emission tomography imaging by using delayed 2-deoxy-2-[F-18]fluoro-d-glucose injection following I.V. insulin in diabetic patients

Molecular Imaging and Biology

Volumn 8, Issue 6, 2006, Pages 348-354

  Turcotte, Eric ^a   Leblanc, Michel ^a   Carpentier, André ^b   Bénard, François ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

Diabetes; FDG; Glucose; Insulin

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; ISOPHANE INSULIN;

ARTICLE; BOLUS INJECTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LUNG NODULE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NON INSULIN DEPENDENT DIABETES MELLITUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; TISSUE DISTRIBUTION; TISSUE LEVEL; WHOLE BODY SCINTISCANNING;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INFUSION PUMPS; INSULIN; LUNG NEOPLASMS; MALE; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

EID: 33750982094     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-006-0064-1     Document Type: Article

References (17)

1. Hustinx R, Benard F, Alavi A (2002) Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med 32(1):35-46
2. Diederichs CG, Staib L, Glatting G, et al. (1998) FDG-PET: Elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 39(6):1030-1033
3. Lindholm P, Minn H, Leskinen-Kallio S, et al. (1993) Influence of the blood glucose concentration on FDG uptake in cancer - a PET study. J Nucl Med 34(1):1-6
4. Torizuka T, Fisher SJ, Brown RS, et al. (1998) Effect of insulin on uptake of FDG by experimental mammary carcinoma in diabetic rats. Radiology 208(2):499-504
5. Wahl RL, Henry CA, Ethier SP (1992) Serum glucose: Effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-d-glucose in rodents with mammary carcinoma. Radiology 183(3):643-647
6. Lewis P, Nunan T, Dynes A, et al. (1996) The use of low-dose intravenous insulin in clinical myocardial F-18 FDG-PET scanning. Clin Nucl Med 21(1):15-18
7. Sherwin RS, Kramer KJ, Tobin JD, et al. (1974) A model of the kinetics of insulin in man. J Clin Invest 53(5):1481-1492
8. Morgan DJ, Bray KM (1994) Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet 26(4):292-307
9. Medina RA, Owen GI (2002) Glucose transporters: Expression, regulation and cancer. Biol Res 35(1):9-26
10. Marom EM, Aloia TA, Moore MB, et al. (2001) Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer 33(2-3):99-107
11. Langen KJ, Braun U, Rota Kops E, et al. (1993) The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 34(3):355-359
12. Crippa F, Gavazzi C, Bozzetti F, et al. (1997) The influence of blood glucose levels on [18F]fluorodeoxyglucose (FDG) uptake in cancer: A PET study in liver metastases from colorectal carcinomas. Tumori 83(4):748-752
13. Torizuka T, Zasadny KR, Wahl RL (1999) Diabetes decreases FDG accumulation in primary lung cancer. Clin Positron Imaging 2(5):281-287
14. Gorenberg M, Hallett WA, O'Doherty MJ (2002) Does diabetes affect [(18)F]FDG standardised uptake values in lung cancer? Eur J Nucl Med Mol Imaging 29(10):1324-1327
15. Chang YC, Yen TC, Ng KK, et al. (2005) Does diabetes mellitus influence the efficacy of FDG-PET in the diagnosis of cervical cancer? Eur J Nucl Med Mol Imaging 32(6):647-652
16. Torizuka T, Fisher SJ, Wahl RL (1997) Insulin-induced hypoglycemia decreases uptake of 2-[F-18]fluoro-2-deoxy-d-glucose into experimental mammary carcinoma. Radiology 203(1):169-172
17. Zhao S, Kuge Y, Tsukamoto E, et al. (2001) Effects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesions. Eur J Nucl Med 28(6):730-735